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INTRODUCTION.	  
Epigene'cs	   is	   the	   study	   of	   the	   group	   of	   heritable	   modiﬁca'ons	   that	   do	   not	   change	   the	  
sequence	  of	  the	  bases	  of	  the	  DNA	  but	  change	  DNA	  conforma'on	  and	  as	  a	  consequence	  the	  
expression	  of	  genes.	  
Epigene'c	  mechanisms	   regulate	   important	   biological	   processes	   like	   the	   ones	   responsible	   of	  
cellular	   division	   and	   diﬀeren'a'on	   involved	   in	   disease	   like	   cancer	   so	   the	   disrup'on	   of	   the	  
epigenome	  contributes	  to	  cancer	  development.	  
Although	  there	  are	  many	  epigene'c	  mechanisms	  altered	  in	  cancer,	  the	  best-­‐studied	  one	  is	  the	  
aberrant	  methyla'on	  of	  DNA.	  	  
DNA	  METHYLATION	  AND	  CANCER.	  
Cancer	   cells	   show	   a	  
diﬀerent	   methyla'on	  
paEern	   compared	   to	  
normal	   cells.	   The	  
hypermethyla'on	  of	  CpG	  
islands	   oHen	   causes	   the	  
transcrip'onal	  
inac'va'on	   of	   tumour	  
suppressor	  genes	  directly	  
driving	   the	   carcinogenic	  
process.	  
Transformed	  cells	  with	  speciﬁc	  hypermethyla'on	  paEerns	  on	  certain	  genes	  are	  reliable	  
biomarkers	  for	  par'cular	  types	  and	  stages	  of	  cancer.	  They	  are	  clinically	  useful	  for	  tumour	  
detec'on,	  outcome	  predic'on,	  treatment	  selec'on	  and	  monitoring.	  
Clinical	  u0lity.	  
DNA	  methyla'on	  can	  be	  found	  in	  several	  types	  of	  biological	  ﬂuids	  so	  it	  can	  be	  obtained	  
noninvasively	  and	  analysed.	  
The	  majority	  of	  methods	   for	  methyla'on	  analysis	  begin	  with	   the	  bisulphite	  conversion	  
that	  creates	  diﬀerent	  sequences	  in	  methylated	  and	  unmethylated	  fragments	  that	  can	  be	  
detected	  by	  a	  variety	  of	  techniques.	  
DNA	  methyla0on	  detec0on	  methods.	  
In	   contrast	   to	   gene'c	   altera'ons,	   gene	   silencing	   by	   epigene'c	   modiﬁca'ons	   is	  
poten'ally	   reversible	   and	   there	   have	   been	   developed	   several	   drugs	   against	   diﬀerent	  
types	  of	  epigene'c	  processes.	  
DNA	  methyltransferase	   inhibitors	   (DNMTi)	   are	   the	   best	   known	  of	   these	   drugs.	   Two	   of	  
them	   (azaci'dine	   and	   decitabine)	   have	   been	   approved	   by	   the	   Food	   and	   Drug	  
Administra'on	   (FDA).	   When	   these	   compounds	   get	   to	   the	   DNA,	   they	   form	   a	   covalent	  
irreversible	  complex	  with	  DNMTs	  trapping	  them.	  
Epigene0c	  therapy.	  
EXAMPLE	  OF	  EPIGENETIC	  THERAPY.	  
It	  was	  found	  taht	  notable	  propor'on	  of	  the	  mutated	  genes	  in	  Myelodysplas'c	  Syndrome	  (MDS)	  aﬀect	  genes	  involved	  in	  epigene'c	  maintenance.	  
The	  most	  well-­‐studied	  altera'on	  is	  the	  aberrant	  DNA	  methyla'on.	  
Epigene'cally	   ac've	   drugs	   azaci'dine	   and	   decitabine	   have	   been	   approved	   for	   treatment	   of	   this	   type	   of	   cancer	   introducing	   a	   new	   op'on	   of	   treatment	   that	   was	   limited	   before	   to	   toxic	   tradi'onal	   induc'on	  
chemotherapeu'cs.	  
-­‐ 	  Improves	  overall	  survival	  (OS)	  
-­‐ 	  Delays	  the	  transforma'on	  to	  AML	  in	  high-­‐grade	  MDS	  pa'ents	  
-­‐ 	  Produces	  signiﬁcant	  responses	  in	  pa'ents	  with	  low	  blast	  count	  AML	  	  
Azaci0dine	  results.	   Decitabine	  results.	  
-­‐ 	  Produces	  red	  blood	  cell	  transfusion-­‐independence	  
-­‐	  Produces	  elonga'on	  of	  progression-­‐free	  survival	  
-­‐	  Improves	  global	  healt	  status	  by	  improving	  fa'gue	  and	  physical	  func'oning.	  
CONCLUSIONS.	  
Epigene'c	  changes	  are	  associated	  with	  cancer	  development	  but	  are	  also	  progressive	  and	  reversible	  and	  these	  makes	  them	  a	  poten'al	  target	  for	  the	  therapeu'c	  interven'on	  and	  	  development	  of	  tumour	  preven'on	  
strategies.	  	  
Aberrant	  methyla'on	  is	  the	  most	  studied	  epigenome	  altera'on	  seen	  in	  cancer.	  The	  purpose	  of	  epigene'c	  therapy	  is	  to	  reverse	  the	  epigene'c	  altera'ons	  in	  cancers	  cells	  and	  restore	  the	  “normal	  epigenome”.	  	  
Of	  all	  the	  DNMTi	  discovered,	  azaci'dine	  and	  decitabine	  have	  already	  demonstrated	  the	  u'lity	  of	  the	  epigene'c	  therapy	  that	  opens	  a	  possibility	  of	  stopping	  some	  types	  of	  cancer	  development	  but	  there	  is	  s'll	  a	  lot	  of	  work	  
to	  do	  ﬁnding	  speciﬁc	  altera'ons	  for	  each	  cancer	  and	  the	  right	  drugs	  and	  doses	  for	  treatment.	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Methyla0on	  patern	  compara0on.	  
Methyla0on	  progression	  from	  normal	  to	  metastasic	  0ssue.	  (Adapted	  
from	  Barillot	  et	  al,	  2012)	  	  
Methodes	  to	  detect	  DNA	  methyla0on	  
and	  comparaison	  of	  their	  features.	  
(Adapted	  from	  Qureshi	  et	  al,	  2010)	  	  
Bisulphite	  modiﬁca0on	  for	  
methyla0on	  assays.	  (Adapted	  
from	  Qureshi	  et	  al,	  2010)	  	  
Mechanisms	  of	  DNMTi	  azaci0dine.	  (Adapted	  from	  Gros	  et	  al,	  2012)	  	  
Overall	  survival	  results.	  (Adapted	  from	  Fenaux	  et	  al,	  2009)	  	   Percentage	  of	  pa0ents	  free	  of	  red	  blood	  cell	  transfusion	  in	  each	  
cycle	  of	  treatment.	  (Adapted	  from	  Kantarjian	  et	  al,	  2006)	  	  
Percentage	  of	  progression-­‐free	  survival	  over	  0me.	  (Adapted	  
from	  Lübbert	  et	  al,	  2011)	  	  
Percentage	  of	  cumula0ve	  incidence	  of	  AML.	  (Adapted	  from	  
Lübbert	  et	  al,	  2011)	  	  
